INTELLECTUAL PROPERTY

Nexien BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.

Nexien's Intellectual Property

Nexien has licensed the intellectual property, including various existing patent applications for the use of cannabinoids and terpenes for exposure to nerve agents.

Nexien has two exclusive licenses covering certain intellectual property,
including certain patent applications. We have also filed five provisional patent applications with the U.S. Patent Office covering formulations that include cannabinoids and/or other substances, including terpenes, formulated for the purpose of treating various medical conditions and disorders.

Current Business Activities

Nexien is currently developing or licensing proprietary delivery systems for cannabinoid‐based medications.

Our 1st technology, XactDose is a patented drug delivery mechanism for cannabinoid-based treatment for humans and animals, offering true and accurate doses with the ease of a simple snap of a scored and pre-divided tablet.